IN A CERTAIN SENSE, Merck & Co.'s decision to cease selling Vioxx, its best-selling painkiller, demonstrates how the peculiarly American combination of government regulation and private-sector ...

Obviously, the FDA would want to be certain that the benefit for using Vioxx in hemophilic arthropathy outweighed the attendant risk before allowing Vioxx (rofecoxib) to be reintroduced to the ...

Merck removed one of the world's best-selling painkillers from the market in 2004 after a study showed Vioxx caused an increased risk of serious cardiovascular events, such as stroke and heart attack.

Patients who took the painkiller Vioxx were at risk of heart attacks and strokes -- something shown by studies conducted years before the product went on the market, a doctor testified Wednesday.

Rofecoxib (Photo credit: Wikipedia) More than a decade ago, Merck launched Vioxx (rofecoxib), one of the first of a new class of pain relievers known as COX-2 inhibitors. These compounds, by ...

Merck & Co. isn't liable for the heart attack of a Kentucky man who took its Vioxx drug, a U.S. jury decided Tuesday in the first trial involving the use of the painkiller after the company issued ...

Vioxx, whose generic name is rofecoxib, went on the market in 1999. It became a "blockbuster," with $2.3 billion in sales in 2003, ...

Vioxx Case Goes To Jury. August 17, 2005 / 4:23 PM EDT / AP Merck & Co. should have told doctors and consumers "the good, the bad and the ugly" about Vioxx long before pulling it from the market ...

Merck & Co., which paid $4.85 billion to resolve lawsuits contending its Vioxx painkiller caused heart attacks, will pay another $23 million to settle claims it duped consumers into buying the drug.

VIOXX was launched in the United States in 1999 and has been marketed in more than ... The results of clinical studies with one molecule in a given class are not necessarily applicable to others ...